Novocure [NVCR] vs Boston Scientific [BSX] Detailed Stock Comparison
Novocure
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Novocure wins in 8 metrics, Boston Scientific wins in 10 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Novocure | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -7.13 | 61.28 | Novocure |
| Price-to-Book Ratio | 3.56 | 6.80 | Novocure |
| Debt-to-Equity Ratio | 200.39 | 53.09 | Boston Scientific |
| PEG Ratio | -7.42 | 36.90 | Novocure |
| EV/EBITDA | -6.50 | 35.51 | Novocure |
| Profit Margin (TTM) | -27.13% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | -24.89% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | N/A | 18.63% | N/A |
| Return on Equity | -48.07% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | -8.64% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $-69.22M | $2.37B | Boston Scientific |
| 1-Year Return | -40.45% | 35.39% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 2.04 | 8.25 | Novocure |
| Enterprise Value | $1.03B | $167.06B | Boston Scientific |
| EV/Revenue Ratio | 1.64 | 9.03 | Novocure |
| Gross Profit Margin (TTM) | 73.88% | 67.65% | Novocure |
| Revenue per Share (TTM) | $6 | $13 | Boston Scientific |
| Earnings per Share (Diluted) | $-1.51 | $1.68 | Boston Scientific |
| Beta (Stock Volatility) | 0.61 | 0.66 | Novocure |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Novocure vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Novocure | -3.30% | -1.68% | -36.44% | -36.18% | -48.59% | -62.89% |
| Boston Scientific | 0.17% | -2.15% | 0.71% | -0.15% | -2.86% | 15.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Novocure | -40.45% | -87.05% | -85.30% | -39.11% | -39.11% | -39.11% |
| Boston Scientific | 35.39% | 143.68% | 163.41% | 491.80% | 1,782.30% | 264.36% |
Performance & Financial Health Analysis: Novocure vs Boston Scientific
| Metric | NVCR | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.29B | $152.55B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,472,605 | 6,789,663 |
| 90 Day Avg. Volume | 1,827,595 | 7,511,608 |
| Last Close | $11.13 | $103.14 |
| 52 Week Range | $10.91 - $34.13 | $74.01 - $108.94 |
| % from 52W High | -67.39% | -5.32% |
| All-Time High | $232.76 (Jun 21, 2021) | $108.94 (Jul 23, 2025) |
| % from All-Time High | -95.22% | -5.32% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.06% | 0.23% |
| Quarterly Earnings Growth | 0.06% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.27% | 0.14% |
| Operating Margin (TTM) | -0.25% | 0.19% |
| Return on Equity (TTM) | -0.48% | 0.12% |
| Debt to Equity (MRQ) | 200.39 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $3.13 | $15.14 |
| Cash per Share (MRQ) | $8.15 | $0.36 |
| Operating Cash Flow (TTM) | $-44,676,000 | $4.28B |
| Levered Free Cash Flow (TTM) | $5.94M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Novocure vs Boston Scientific
| Metric | NVCR | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -7.13 | 61.28 |
| Forward P/E | -7.42 | 36.90 |
| PEG Ratio | -7.42 | 36.90 |
| Price to Sales (TTM) | 2.04 | 8.25 |
| Price to Book (MRQ) | 3.56 | 6.80 |
| Market Capitalization | ||
| Market Capitalization | $1.29B | $152.55B |
| Enterprise Value | $1.03B | $167.06B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.64 | 9.03 |
| Enterprise to EBITDA | -6.50 | 35.51 |
| Risk & Other Metrics | ||
| Beta | 0.61 | 0.66 |
| Book Value per Share (MRQ) | $3.13 | $15.14 |
Financial Statements Comparison: Novocure vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NVCR | BSX |
|---|---|---|
| Revenue/Sales | $154.99M | $4.66B |
| Cost of Goods Sold | $38.52M | $1.45B |
| Gross Profit | $116.47M | $3.21B |
| Research & Development | $53.78M | $443.00M |
| Operating Income (EBIT) | $-37.87M | $937.00M |
| EBITDA | $-34.54M | $1.23B |
| Pre-Tax Income | $-30.30M | $805.00M |
| Income Tax | $4.02M | $133.00M |
| Net Income (Profit) | $-34.32M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NVCR | BSX |
|---|---|---|
| Cash & Equivalents | $127.28M | $725.00M |
| Total Current Assets | $1.09B | $7.34B |
| Total Current Liabilities | $743.31M | $5.06B |
| Long-Term Debt | $137.76M | $10.93B |
| Total Shareholders Equity | $361.96M | $22.45B |
| Retained Earnings | $-1.19B | $3.35B |
| Property, Plant & Equipment | $145.02M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NVCR | BSX |
|---|---|---|
| Operating Cash Flow | $-14.80M | $513.00M |
| Capital Expenditures | $-10.61M | $-187.00M |
| Free Cash Flow | $-46.28M | $277.00M |
| Debt Repayment | $0 | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NVCR | BSX |
|---|---|---|
| Shares Short | 4.93M | 19.57M |
| Short Ratio | 3.87 | 2.65 |
| Short % of Float | 0.07% | 0.01% |
| Average Daily Volume (10 Day) | 2,472,605 | 6,789,663 |
| Average Daily Volume (90 Day) | 1,827,595 | 7,511,608 |
| Shares Outstanding | 108.52M | 1.47B |
| Float Shares | 94.16M | 1.48B |
| % Held by Insiders | 0.10% | 0.00% |
| % Held by Institutions | 0.79% | 0.94% |
Dividend Analysis & Yield Comparison: Novocure vs Boston Scientific
| Metric | NVCR | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |